Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03652077 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
A Phase 1 study of Melanoma and Gastric Cancer, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT03652077: Completed Phase 1 study of Melanoma and Gastric Cancer, sponsored by Incyte Corporation.
NCT03652077 is a Phase 1 study of Melanoma and Gastric Cancer that has completed, run by Incyte Corporation. The registered enrollment target is 40 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03652077, a Phase 1 study of Melanoma and Gastric Cancer, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Primary Outcome
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.
Conditions Studied
Interventions
- DRUG INCAGN02390
Study Locations (4)
California
- The Angeles Clinical and Research Institute - Los Angeles
Mississippi
- University of Mississippi - Jackson
New Jersey
- Hackensack Medical Center - Hackensack
North Carolina
- Carolina BioOncology - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2021-08-18 |
| Phase | Phase 1 |
What the finished NCT03652077 record still lists
NCT03652077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower).
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which INCAGN02390 is the first listed.
NCT03652077 reports a single indexed study location in California, Mississippi, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03652077 about?
NCT03652077 is a clinical study titled "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies". The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
What is the current status of trial NCT03652077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-09-24. Estimated completion is 2021-08-18.
What conditions does trial NCT03652077 study?
This clinical trial studies the following conditions: Melanoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Esophageal Cancer.
What interventions are being tested in trial NCT03652077?
The interventions under investigation include: INCAGN02390 (DRUG).
Who is sponsoring clinical trial NCT03652077?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03652077 being conducted?
This trial has 4 study locations across California, Mississippi, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03652077's enrollment target sits among peer trials
40 177th of 266 higher than 85 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI